CSIMarket
 
Ispecimen inc   (NASDAQ: ISPC)
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

Ispecimen Inc's Customers Performance

ISPC



 
ISPC's Source of Revenues During the corresponding time, Ispecimen Inc saw a revenue deteriorated by -78.69 % year on year, sequentially revenue fell by -2.61 %. While revenue at the Ispecimen Inc 's corporate clients

List of ISPC Customers




for the same period Ispecimen Inc revnue deteriorated by -78.69 % year on year, sequentially revenue fell by -2.61 %.

List of ISPC Customers

Ispecimen Inc's Business Units
Asia Pacific    31.58 % of total Revenue






Ispecimen Inc's Comment on Sales, Marketing and Customers



iSpecimen operates the iSpecimen Marketplace platform, which provides healthcare researchers and supply organizations access to de-identified healthcare data. As of December 31, 2025, the platform includes approximately 19 million patient records, 105 million clinical specimen records, 1.4 million banked specimen records, and 1.2 million medical conditions. Researchers use the platform to search for and acquire human biospecimens and associated data to support their research programs. Supply organizations contribute to medical research and generate revenue through the platform. iSpecimen plans to enhance the platform by improving matchmaking, search and workflow capabilities, automation, and pricing availability to better support prospects, customers, sales and operations staff, and supply partners. The company focuses on improving customer experience, supplier engagement, and operational efficiency to scale its business model.





Ispecimen Inc’s Comment on Sales, Marketing and Customers


iSpecimen operates the iSpecimen Marketplace platform, which provides healthcare researchers and supply organizations access to de-identified healthcare data. As of December 31, 2025, the platform includes approximately 19 million patient records, 105 million clinical specimen records, 1.4 million banked specimen records, and 1.2 million medical conditions. Researchers use the platform to search for and acquire human biospecimens and associated data to support their research programs. Supply organizations contribute to medical research and generate revenue through the platform. iSpecimen plans to enhance the platform by improving matchmaking, search and workflow capabilities, automation, and pricing availability to better support prospects, customers, sales and operations staff, and supply partners. The company focuses on improving customer experience, supplier engagement, and operational efficiency to scale its business model.








ISPC's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Ispecimen inc 2.09 1.03 -11.10 7
SUBTOTAL 0.00 0.00 0.00 -

Sources: Ispecimen inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ispecimen inc’s corporate clients.
For your research, we’ve provided 9 tables on Ispecimen inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.